KIFFIK Biomedical has strengthened its leadership team with two strategic appointments aimed at accelerating the development and commercialization of its interstitial fluid (ISF)-based diagnostic platform. The Providence, Rhode Island-based company announced that healthcare development executive Rene Veloso has joined as Chief Investment Officer, while Dr. Reginald Swift, CEO of Rubix Life Sciences, will serve as fractional Chief Scientific Officer.
Leadership Expansion to Drive Growth
"The addition of Rene and Reggie to our already strong leadership team is a game-changer as we embark on our next chapter of growth," said George Cagna, CEO of KIFFIK Biomedical. "Ensuring our R&D function is meeting the highest scientific standards, coupled with securing operating capital, empowers our team to bring next-generation ISF biomonitoring to partners and patients."
As Chief Investment Officer, Veloso will focus on securing capital investments from institutional partners interested in unlocking the potential of interstitial fluid real-time monitoring for cancer and other diseases. Veloso brings significant experience from his previous role as Senior Vice President at Locust Walk Partners, LLC, where he led multiple high-profile merger and acquisition activities on behalf of biopharmaceutical clients.
Scientific Leadership and Strategic Partnerships
Dr. Swift's appointment as fractional CSO builds on an existing relationship between KIFFIK and his company, Rubix Life Sciences, which specializes in aptamer-based precision medicine. The two companies established a strategic partnership earlier this year to advance next-generation ISF extraction technology. In his new role, Dr. Swift will help shape KIFFIK's clinical operations to ensure research and development activities meet the highest scientific standards.
Needle-Free Diagnostic Innovation
KIFFIK's proprietary and patented KIFFIK EXP platform represents a significant advancement in non-invasive diagnostics, offering needle-free, real-time disease detection and health monitoring through interstitial fluid analysis. The technology focuses on biomarker detection for oncology applications and therapeutic monitoring, positioning the company at the forefront of precision medicine diagnostics.
The interstitial fluid-based approach provides what the company describes as high-precision, accessible, and patient-friendly solutions that could enable earlier disease detection and improved health outcomes. This technology addresses the growing demand for non-invasive diagnostic methods that can provide real-time monitoring capabilities for various medical conditions.
